Journal Home
Search for

Volume 38, Issue 1, Pages 7-13 (January 2007)


View previous. 3 of 18 View next.

Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing

Laura De Marcoa, Anna Gillio-TosaCorresponding Author Informationemail address, Lisa Bonellob, Valeria Ghisettic, Guglielmo Roncod, Franco Merlettiad

Received 23 May 2006; received in revised form 12 September 2006; accepted 14 September 2006. published online 30 October 2006.

Abstract 

Background

Persistent infections with high-risk types of human papillomavirus (HR-HPV) favour integration of viral DNA into the host cells and are associated with cervical carcinoma. HPV16 is the prevalent HR-type worldwide associated to cervical cancer. Integration of viral DNA promotes a selective cell growth advantage, resulting a risk factor for cancer development.

Objectives

To test physical status of HPV16 infection in pre-neoplastic cervical lesions using a quantitative real time-PCR (QRT-PCR) based method. To investigate reliability of this method in identification of HPV16 integrated sequences, by detection of integrated papillomavirus sequences (DIPS-PCR) assay and sequencing.

Study design

One hundred and seventy HR-HPV positive archival cervical specimens were tested for presence of HPV16 DNA. In HPV16 positive samples, viral load and physical status were evaluated.

Results

HPV16 DNA was detected in 74/170 (43%) HR-HPV positive specimens. In 52/74 a QRT-PCR was performed, and 3 integrated, 13 mixed and 36 episomal forms were detected. Presence of integrated forms was confirmed by DIPS-PCR and sequencing.

Conclusions

Presence of HPV integrated forms was detected and confirmed in pre-neoplastic cervical lesions. The QRT-PCR method we used is sensitive and specific for identification of HPV integration in cervical samples, and may be suitable for large scale investigations with prognostic and clinical implications in management of cervical cancer.

a Unit of Cancer Epidemiology, C.E.R.M.S., University of Turin, via Santena 7, 10126 Turin, Italy

b Unit of Molecular Oncology, C.E.R.M.S., University of Turin, via Santena 7, 10126 Turin, Italy

c Unit of Microbiology, Ospedale S.Giovanni Battista, corso Bramante 80, 10126 Turin, Italy

d Center for Oncologic Prevention, via S.Francesco da Paola 31, 10126 Turin, Italy

Corresponding Author InformationCorresponding author. Tel.: +39 011 633 6863; fax: +39 011 633 4664.

PII: S1386-6532(06)00344-1

doi:10.1016/j.jcv.2006.09.008


View previous. 3 of 18 View next.